Search Technologies
Displaying 31 - 40 of 84 results
Researchers at the University of Maryland have created hundreds of innovations that are available for licensing. Our Discovery Portfolio contains an exciting mix of vaccines, drug targets, therapeutics, devices and cutting edge techniques that promise to make a quantifiable impact on human health and the environment.
Search by keyword:
-
Giant obscurins and their uses in cancer prognosis and therapy
Published Wednesday, February 7, 2018Approximately 20% of cancer patients diagnosed annually in the US have metastatic cancer, which is associated with much poorer prognoses compared to patients with localized disease. Accurately determining which patients are at risk of developing metastases is a major clinical challenge. Giant obscurins, encoded by the single obscn gene, are...
Investigator(s): Aikaterini Kontrogianni-Konstantopoulos, Konstantinos Konstantopoulos, Marey Shriver, Nicole Perry
Categories: Biomarker, Therapeutics, Biologics
Keyword(s): oncology, antibody
Docket: AK-2013-059
-
Small molecule inhibitors of the Mcl-1 oncoprotein based on a 1-hydroxy-2-naphthoate scaffold
Published Monday, January 29, 2018Myeloid cell leukemia-1 (Mcl-1) is an oncoprotein over-expressed in multiple human cancers and is responsible for resistance to conventional anti-cancer agents. An anti-apoptotic member of the Bcl-2 protein family, Mcl-1 plays a major role in the homeostasis of cell proliferation and cell death. The cell-killing function of the pro-apoptotic...
Investigator(s): Steven Fletcher, Maryanna Lanning, Lijia Chen
Categories: Therapeutics, Small molecules
Keyword(s): oncology
Docket: SF-2014-103
-
Anthrax toxin protective antigen proteins engineered to target membrane-anchored serine proteases overexpressed on tumor cells
Published Friday, January 26, 2018Bacillus anthracis is the bacterium that produces the anthrax toxin, which consists of the three distinct proteins protective antigen (PrAg), lethal factor (LF), and edema factor (EF). In order for the toxin to be activated, the PrAg moiety of the toxin must bind to cell-surface proteins and become proteolytically cleaved by the proprotein...
Investigator(s): Toni Antalis, Erik Martin
Categories: Therapeutics, Biologics
Keyword(s): oncology, protein therapy, anthraz, ZMT
Docket: TA-2016-015
-
Histatin-5-Based Antifungal Peptides for Oral Topical Applications
Published Tuesday, October 31, 2017Candida albicans is a fungus colonizing human mucosal surface. It commonly causes recurrent infections which can become life-threatening in immunosuppressed and immunocompromised patients. Histatin-5 (Hst-5) is a cationic antimicrobial peptide found in saliva with antifungal activity against C. albicans, related fungal...
Investigator(s): Mary Ann Jabra-Rizk, Amy Karlsson, Timothy F. Meiller
Categories: Therapeutics, Biologics
Keyword(s): Candida, fungus, Biofilm, antimicrobial
Docket: MR-2016-100
-
Rational Targeting of Protein Translation in Cancer Cells
Published Wednesday, June 14, 2017Deregulation of protein translation is associated with a growing number of human diseases, including tumorigenesis. The mammalian mTOR pathway has garnered considerable interest as a major target for new anti-cancer therapies due to its key role in regulating cell growth. However, clinical applications have been limited due to the role of this...
Investigator(s): France Carrier
Categories: Therapeutics
Keyword(s): oncology, mROR
Docket: FC-2015-047
-
New Compounds to Treat Metastatic and Triple Negative Breast Cancer
Published Wednesday, May 31, 2017Despite multi-modal treatment, approximately 40% of all women with breast cancer will suffer a recurrence. While the 10-year overall survival rate for women without recurrence is 84%, this drops to 49%-72% for women with a locoregional recurrence or a second primary malignancy. Luminal breast cancer has the highest rates of relapse, often...
Investigator(s): Antonino Passaniti, Alexander MacKerell
Categories: Therapeutics, Small molecules
Keyword(s): breast cancer, oncolytic, small molecule, CADD
Docket: AP-2015-080
-
Inhibition of Galectin 3 Binding to the Airway Epithelial Surface to Treat or Prevent Septic Shock Resulting from Influenza and Subsequent Pneumococcal Pneumonia Infection
Published Tuesday, May 2, 2017The main cause of death during influenza pandemics is Streptococcus pneumoniae co-infection, which results in hyperinflammatory response leading to sepsis. While the exact mechanism behind this complication is not understood, influenza infection predisposes patients to pneumococcal pneumonia that often progresses to uncontrolled...
Investigator(s): Gerardo R. Vasta, Lai-Xi Wang
Categories: Therapeutics
Keyword(s): sepsis, influenza, antiinflammatory
Docket: GV-2015-133
-
Correction of Ischemia with p53 Inhibitors: A Novel Therapeutic Approach to Induce Arteriogenesis
Published Friday, February 24, 2017Severe obstruction of the arteries and reduced blood flow (critical limb ischemia(CLI)) is the advanced stage of peripheral artery disease (PAD). Investigators at UMB have found that Pifithrin-α, a p53 pharmacological inhibitor, improves limb perfusion in diabetic animals, suggesting a therapeutic role in CLI. Tumor-suppressing...
Investigator(s): Rajabrata Sarkar, Mark Hoofnagle, Subhradip Mukhopadhyay
Categories: Therapeutics, Methods of Treatment
Keyword(s): cardiovascular
Docket: RS-2013-040
-
Treatment of depression, anhedonia, chronic stress conditions and PTSD with (2R6R)-HNK
Published Thursday, November 10, 2016Ketamine exerts rapid and sustained antidepressant effects after a single dose in patients with depression, but its use is associated with undesirable side effects. With the novel discovery of the actions of ketamine metabolites on the AMPA and not the NMDA glutamate receptors as previously reported,...
Investigator(s): Todd Gould, Panos Zanos, Irving Wainer, Carl Zarate, Craig Thomas, Patrick Morris, Ruin Moaddel
Categories: Therapeutics, Small molecules
Keyword(s): Therapeutic, depression, CNS
Docket: TG-2015-116, TG-2016-107
-
DART Therapeutic Platform Technology for Treating Fn14-Positive Cancers
Published Monday, June 13, 2016Therapeutic nanoparticles (NPs) approved for clinical use in cancer patients provide only modest improvements in patient survival, likely due to a number of delivery challenges. The discovery of unique cell surface proteins associated with certain tumors has facilitated new approaches for nanocarrier design and payload delivery; specifically,...
Investigator(s): Anthony Kim, Jeffrey Winkles, Graeme Woodworth
Categories: Therapeutics, Nanotechnology + Nanoparticles + Nanomaterials
Keyword(s): blood brain barrier, diagnostic, Therapeutic, brain cancer, nanoparticle
Docket: GW-2014-120; AK-2019-061